Search

Your search keyword '"Revheim, Mona-Elisabeth"' showing total 7 results
Start Over Author "Revheim, Mona-Elisabeth" Journal blood
7 results on '"Revheim, Mona-Elisabeth"'

1. Carfilzomib-Lenalidomide-Dexamethasone Consolidation in Myeloma Patients with a Positive FDG PET/CT after Upfront Autologous Stem Cell Transplantation: A Phase II Study (CONPET)

Author

Nørgaard, Jakob Nordberg, primary, Abildgaard, Niels, additional, Lysén, Anna, additional, Tsykunova, Galina, additional, Vangsted, Annette Juul, additional, João, Cristina, additional, Remen, Nora, additional, Connelly, James P, additional, Revheim, Mona-Elisabeth R., additional, and Schjesvold, Fredrik H., additional

Published
2021
Full Text
View/download PDF

3. 177lu-Satetraxetan-Lilotomab in the Treatment of Patients with Indolent Non-Hodgkin B-Cell Lymphoma (NHL), Phase 1/2 Safety and Efficacy Data from Four Different Pre-Dosing Regimens

Author

Kolstad, Arne, primary, Madsbu, Ulf, additional, Beasley, Matthew, additional, Bayne, Michael, additional, Illidge, Tim, additional, O'Rourke, Noelle, additional, Stokke, Caroline, additional, Bach-Gansmo, Tore, additional, Løndalen, Ayca Muftuler, additional, Holtedahl, Jon Erik, additional, Revheim, Mona Elisabeth, additional, Bruland, Øyvind, additional, Dahle, Jostein, additional, Baylor Curtis, Laurie, additional, Østengen, Åse, additional, Turner, Simon, additional, Bolstad, Nils, additional, Hartvig Larsen, Roy, additional, Spetalen, Signe, additional, Erlanson, Martin, additional, Nygaard Rudå, Stine, additional, and Holte, Harald, additional

Published
2016
Full Text
View/download PDF

4. Efficacy and Safety Results of a Phase 1 Study of 177 lu-DOTA-HH1 (Betalutin®) with and without HH1 Pre-Dosing for Patients with Relapsed CD37+ Non-Hodgkin B Cell Lymphoma (NHL)

Author

Kolstad, Arne, primary, Madsbu, Ulf, additional, Bolstad, Bjørg, additional, Stokke, Caroline, additional, Bach-Gansmo, Tore, additional, Muftuler Løndalen, Ayca, additional, Holtedahl, Jon Erik, additional, Revheim, Mona Elisabeth, additional, Bruland, Øyvind, additional, Dahle, Jostein, additional, Bolstad, Nils, additional, Hartvig Larsen, Roy, additional, Spetalen, Signe, additional, Erlanson, Martin, additional, Nygaard Rudå, Stine, additional, and Holte, Harald, additional

Published
2015
Full Text
View/download PDF

5. A Phase I Study of 177 lu-DOTA-HH1 (Betalutin) Radioimmunotherapy for Patients with Relapsed CD37+ Non-Hodgkin's B Cell Lymphoma

Author

Kolstad, Arne, primary, Madsbu, Ulf, additional, Dahle, Jostein, additional, Stokke, Caroline, additional, Bach-Gansmo, Tore, additional, Muftuler Løndalen, Ayca, additional, Holtedahl, Jon Erik, additional, Revheim, Mona Elisabeth, additional, Bruland, Øyvind, additional, Bolstad, Bjørg, additional, Bolstad, Nils, additional, Tierens, Anne, additional, Larsen, Roy Hartvig, additional, Alfheim, Jan Alan, additional, Delabie, Jan, additional, Signe, Spetalen, additional, Erlanson, Martin, additional, Nygaard Rudå, Stine, additional, and Holte, Harald, additional

Published
2014
Full Text
View/download PDF

6. Efficacy and Safety Results of a Phase 1 Study of 177lu-DOTA-HH1 (Betalutin®) with and without HH1 Pre-Dosing for Patients with Relapsed CD37+ Non-Hodgkin B Cell Lymphoma (NHL)

Author

Kolstad, Arne, Madsbu, Ulf, Bolstad, Bjørg, Stokke, Caroline, Bach-Gansmo, Tore, Muftuler Løndalen, Ayca, Holtedahl, Jon Erik, Revheim, Mona Elisabeth, Bruland, Øyvind, Dahle, Jostein, Bolstad, Nils, Hartvig Larsen, Roy, Spetalen, Signe, Erlanson, Martin, Nygaard Rudå, Stine, and Holte, Harald

Abstract

Background:

Published
2015
Full Text
View/download PDF

7. A Phase I Study of 177lu-DOTA-HH1 (Betalutin) Radioimmunotherapy for Patients with Relapsed CD37+ Non-Hodgkin’s B Cell Lymphoma

Author

Kolstad, Arne, Madsbu, Ulf, Dahle, Jostein, Stokke, Caroline, Bach-Gansmo, Tore, Muftuler Løndalen, Ayca, Holtedahl, Jon Erik, Revheim, Mona Elisabeth, Bruland, Øyvind, Bolstad, Bjørg, Bolstad, Nils, Tierens, Anne, Larsen, Roy Hartvig, Alfheim, Jan Alan, Delabie, Jan, Signe, Spetalen, Erlanson, Martin, Nygaard Rudå, Stine, and Holte, Harald

Abstract

Background and aim:The CD37 antigen is expressed at high levels predominantly by normal B cells and the majority of malignant B-cell lymphomas. Hence, this surface antigen represents an interesting therapeutic target for treatment of B-cell non-Hodgkin lymphomas (NHL). 177Lu-DOTA-HH1 (Betalutin™) is a novel anti-CD37 radioimmunoconjugate currently under clinical development. Betalutin™ consists of the β-emitting isotope Lutetium-177 (t/2 = 6.7 days) chelated to DOTA (a chemical linker) which is conjugated to the murine mAb HH1. Betalutin™ is delivered in a ready-to-use formulation at the study centers. Pre-clinical studies have demonstrated significant anti-tumor activity; both ex vivo and in models of human B-cell lymphomas in mice. Based on these results, a phase I study has been initiated in order to determine the maximum tolerated dose (MTD), overall safety and to explore tumor response.

Published
2014
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results